Prospective, longitudinal, open label, HIV-2 viral load and antiretroviral resistance
informed 2nd-line ARV implementation study.
Phase:
N/A
Details
Lead Sponsor:
University of Washington
Collaborators:
Centre de Sante de Ziguinchor, Casamance, Senegal Clinique des Maladies Infectieuses, CHNU de Fann, Dakar, Senegal Janssen Pharmaceutica Merck Sharp & Dohme Corp. National Institute of Allergy and Infectious Diseases (NIAID)